Biocytogen’s antibody BD & Licensing team will present a poster entitled “Discovery of RenNano®-derived human heavy-chain-only TFR1 antibodies that can efficiently cross the blood-brain barrier and deliver drug payloads” at the upcoming 5th annual CNS Drug Delivery Summit, held in Boston, US from December 5-7, 2023.
TFR1 heavy-chain-only antibodies (HCAbs) discovered from Biocytogen’s proprietary fully human nanobody mice (RenNano® mice) demonstrate optimal in vitro nM range affinity and internalization capacity. In vivo experiments further show that the HCAbs can efficiently cross the blood-brain barrier and deliver payloads with favorable pharmacokinetic properties, making them ideal for future drug development.
The ability of RenNano® mice to generate diverse HCAb sequences with favorable affinity facilitates the discovery of fully human nanobodies with reduced time, cost and risk, as in vitro humanization is not necessary. In addition to the potential to be developed into nanobodies with superior tissue penetration ability, RenNano-derived HCAbs can also be directly assembled into bi-/multi-specific antibodies or cell therapies.
The development of RenNano® mice led to the launch of Biocytogen’s “Nano 100 Project” early this year, which aims to develop fully human nanobody drugs for more than 100 targets, including tumor associated antigens (TAAs), immune-checkpoints, cytokines, GPCRs, and factors related to neurological diseases. In addition to TFR1, fully human nanobody sequences for more than 20 targets have been obtained in the chart below. To learn more about Biocytogen’s off-the-shelf nanobodies, or to start a novel nanobody discovery project, stop by the poster or contact our team at BD-Licensing@biocytogen.com.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company focused on the research and development of novel antibody-based drugs. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline is comprised of 10 core assets, with partnerships also established for multiple clinical assets.
Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides 1700+ off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
